A phase 3 study assessed the efficacy and safety of plitidepsin (Aplidin) in combination with dexamethasone in patients with relapsed/refractory multiple myeloma.
Researchers find 4 genetic variants that are strongly associated with the risk of acute lymphoblastic leukemia in children with Down syndrome.
Study finds health-related quality of life is often not collected for novel cancer drugs when they are submitted for reimbursement.
Two cell mutations have been linked to acute myeloid leukemia, but the reason for their cooperation has been unknown.
Study shows the importance of a cancer-causing oncogene, known as SET/TAF1, in triggering cancer cell proliferation.
Daratumumab was approved based on results from part one of the Phase III CASSIOPEIA study.
Study indicated that patients who received radiation 30 days or fewer before their CAR T-cell infusion did not experience serious cytokine release syndrome or neurotoxicity.
Patients with diabetes demonstrated a higher likelihood of developing non-Hodgkin lymphoma than those without diabetes, especially among men.
Top news of the day from across the health care landscape.
Hematology and oncology pharmacists discussed patient outreach at a panel during the Hematology/Oncology Pharmacy Association’s (HOPA) annual conference in April.
A new study identified pathways that may serve as therapeutic targets for overcoming drug resistance in acute myeloid leukemia.
Immunotherapy methods emerged on the oncology market as adoptive cell transfers, specifically chimeric antigen receptor (CAR) T-cell therapies, with clear benefits in hematologic malignancy treatment.